Methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Canada

被引:24
作者
Webster, Duncan
Rennie, Robert P. [1 ]
Brosnikoff, Cheryl L.
Chui, Linda
Brown, Connie
机构
[1] Univ Alberta Hosp, Med Microbiol Lab, Edmonton, AB T6G 2J2, Canada
[2] Dynacare Kasper Med Labs, Edmonton, AB T5J 5E2, Canada
[3] Univ Alberta Hosp, Div Infect Dis, Dept Internal Med, Edmonton, AB T6G 2R7, Canada
关键词
vancomycin; MRSA; reduced susceptibility; Canada;
D O I
10.1016/j.diagmicrobio.2006.07.007
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This study defines the characteristics of decreasing vancomycin susceptibility in multiple isolates of methicillin-resistant Stapkilococcus aureus (MRSA) recovered from a hospitalized patient in Canada over a period of 6 months. The MICs of the isolates increased during therapy with vancomycin. The patient fractured her right hip while in the United States. She was started on treatment with vancomycin. The MICs of successive isolates increased from <= 1 to 4 mg/L over 6 months. Then, an isolate tested at 8 mg/L initially and 4 mg/L with confirmatory E-test (AB BIODISK, Solna, Sweden). One month later, MRSA was still present in her wound, and therapy was changed to linezolid with rifampin. Subsequent cultures were negative for MRSA. Susceptibility testing was performed on the BD Phoenix (Becton Dickinson Diagnostic Systems, Sparks, MD), Dade Microscan (Dade Behring Microscan, Sacramento, CA), Pasco MIC (Becton Dickinson, Sparks, MD), Vitek 2 (bioMerieux, St. Louis, MO), and Sensititre (Trek Diagnostic Systems, Cleveland, OH) systems, and by E-test. Molecular typing (pulsed-field gel electrophoresis [PFGE]) was used to verify the relatedness of the isolates. Transmission electron microscopy (TEM) was used to assess the cell wall thickness of isolates with differing MICs. Population analysis was performed to assess for vancomycin hetero-resistance. MICs of 4 mg/L were only obtained with BD Phoenix, E-test, and broth microdilution. All isolates were identical by PFGE. The most resistant isolate had a thicker cell wall on TEM. Vancomycin hetero-resistance was observed in the resistant isolates. This is the first strain of MRSA with reduced susceptibility to vancomycin reported in Canada. The breakpoints for vancomycin susceptibility have been revised in light of such observations. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:177 / 181
页数:5
相关论文
共 16 条
[1]  
*CAN COMM DIS, 2005, 3102 CAN COMM, P33
[2]   Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene [J].
Chang, S ;
Sievert, DM ;
Hageman, JC ;
Boulton, ML ;
Tenover, FC ;
Downes, FP ;
Shah, S ;
Rudrik, JT ;
Pupp, GR ;
Brown, WJ ;
Cardo, D ;
Fridkin, SK .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (14) :1342-1347
[3]  
Clinical and Laboratory Standards Institute, 2006, M7A7 CLSI
[4]   Staphylococcus aureus with reduced susceptibility to vancomycin [J].
Cosgrove, SE ;
Carroll, KC ;
Perl, TM .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (04) :539-545
[5]   THE EPIDEMIOLOGY OF INTRAVENOUS VANCOMYCIN USAGE IN A UNIVERSITY HOSPITAL - A 10-YEAR STUDY [J].
ENA, J ;
DICK, RW ;
JONES, RN ;
WENZEL, RP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (05) :598-602
[6]   Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001 [J].
Fridkin, SK ;
Hageman, J ;
McDougal, LK ;
Mohammed, J ;
Jarvis, WR ;
Perl, TM ;
Tenover, FC .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (04) :429-439
[7]  
Fridkin SK, 2001, CLIN INFECT DIS, V32, P108, DOI 10.1086/317542
[8]   Outbreak in Alberta of community-acquired (USA300) methicillin-resistant Staphylococcus aureus in people with a history of drug use, homelessness or incarceration [J].
Gilbert, Mark ;
MacDonald, Judy ;
Gregson, Dan ;
Siushansian, Jennifer ;
Zhang, Kunyan ;
Elsayed, Sameer ;
Laupland, Kevin ;
Louie, Tom ;
Hope, Karen ;
Mulvey, Michael ;
Gillespie, John ;
Nielsen, Diane ;
Wheeler, Virginia ;
Louie, Marie ;
Honish, Agnes ;
Keays, Gloria ;
Conly, John .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2006, 175 (02) :149-154
[9]  
HIAMATSU K, 1997, J ANTIMICROB CHEMOTH, V30, P135
[10]  
Hiramatsu K, 2001, Lancet Infect Dis, V1, P147, DOI 10.1016/S1473-3099(01)00091-3